Health
A Startup Is Getting $35 Million to Find Culprits Behind Brain Infections
- Delve Bio will sell tests to seek out rare, exotic pathogens
- Perceptive Xontogeny, Google Ventures are among funders
This article is for subscribers only.
Genetic researchers are taking $35 million in venture funds to start a company aimed at identifying mysterious pathogens in the brain and unraveling infection mysteries.
A collaboration between scientists at the University of California, San Francisco and Harvard University, Delve Bio will sell tests to detect brain-eating amoebas, rare fungi and other exotic infections. First-round funds from Perceptive Xontogeny Ventures, Section 32, Google Ventures and other investors will help Delve advance genetic diagnostic tools to do its detective work.